LOS ANGELES, CA -- (Marketwired) -- 04/04/13 -- Anyone who has ever had a family member or friend afflicted with cancer knows first hand that the treatments they must endure seem far more devastating than the disease itself. An exciting video released by CEL-SCI (NYSE Amex: CVM) earlier this week gave investors a first ever glimpse at the manufacturing facility outside of Baltimore where scientists hope all of that is about to change.
We've noted before that CEL-SCI shares appear to be trading at undervalued levels given that the company is so far along in its development process (currently in PHASE III clinical trials), but last week shares took a hit for no apparent reason. That prompted several insiders at the company, led by Chief Executive Officer, Geert Kersten, to buy nearly 400,000 shares at discounted prices. Within a couple of sessions, shares bounced back to the $.25 level where they had been trading for some time, but still below their 50-day moving average.
Investors have taken notice that this is the first time since 2008 that Kersten has purchased shares in the open market and that the stock saw some appreciation not long after those purchases. That leads some, including myself, to speculate that there may be some positive developments and news flow ahead for the company.
This company has been around for a long time and it has prompted some to ask tough questions about their efforts. CEL-SCI critics paint the company as far too secretive for a firm that has been at this game too long. Perhaps the release of this new video footage can change some of that?
In one video interview last October, CEO Kersten defended his firm acknowledging that "This is the first cancer drug being developed as a true first line therapy, meaning before you get surgery, radiation or chemotherapy, we would boost your immune system. Everybody today boosts your immune system after having destroyed it. Doesn't make much logical sense, right? So everything we do is different."
In the finance.yahoo.com%2fnews%2fcel-sci-corporation-releases-video-120000959.html">newly released video titled "The CEL-SCI Story" much time is spent highlighting the work the company has been doing for those 25 years, showcasing CEL-SCI's promising cancer immunotherapy, Multikine.
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Allstate Seeks to Invest in Minority Firms
- SpaceX's Satellite Launch Is 'Game-Changer'
- Latin Music Conference Turns 25
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Newtown Massacre Heard on 911 Recordings
- Reid Confident Congress to Pass Immigration Bill
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Climate Change Early Warning System Urged